DiaMedica Therapeutics
DMAC
78 hedge funds and large institutions have $82.8M invested in DiaMedica Therapeutics in 2025 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 31 increasing their positions, 11 reducing their positions, and 4 closing their positions.
500% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 4
182% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 11
142% more capital invested
Capital invested by funds: $34.2M → $82.8M (+$48.6M)
34% more funds holding
Funds holding: 58 → 78 (+20)
23% more call options, than puts
Call options by funds: $178K | Put options by funds: $145K
4.24% more ownership
Funds ownership: 20.44% → 24.68% (+4.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CLG
Cooperman Leon G
|
+$8.79M |
| 2 |
Millennium Management
New York
|
+$6.44M |
| 3 |
BlackRock
New York
|
+$2.64M |
| 4 |
Morgan Stanley
New York
|
+$1.84M |
| 5 |
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Dallas,
Texas
|
+$1.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.72M |
| 2 |
First Manhattan
New York
|
-$550K |
| 3 |
PWM
Perigon Wealth Management
San Francisco,
California
|
-$207K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$191K |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$123K |
DMAC Hedge Fund Activity: Q3 2025 in Review
78 of the 7,626 institutional investors tracked by Wall St. Rank reported a position in DiaMedica Therapeutics (DMAC) for Q3 2025, worth a combined $82.8M — up 142% from $34.2M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new DMAC positions and 4 closed out — a net gain of 20 holders — while 31 added to existing stakes and 11 trimmed.
The largest buyer was Cooperman Leon G, adding an estimated $8.79M. The largest seller was Vanguard Group, cutting an estimated $4.72M.
- 78 institutional investors held DiaMedica Therapeutics (DMAC) as of Q3 2025, up from 58 in Q2 2025.
- Funds reported $82.8M of DiaMedica Therapeutics stock for Q3 2025, up 142% quarter-over-quarter.
- 24 funds opened new DiaMedica Therapeutics positions in Q3 2025 and 4 closed out, a net change of +20 holders.
- The largest DiaMedica Therapeutics buyer in Q3 2025 was Cooperman Leon G, an estimated $8.79M added.
- The largest DiaMedica Therapeutics seller in Q3 2025 was Vanguard Group, an estimated $4.72M sold.
Based on aggregated 13F filings for Q3 2025.